retatrutide nonalcoholic steatohepatitis trial Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Retatrutide for weight loss: Study

Retatrutide is often described as 8.9 times native GIP potency, 0.40 times native GLP-1 potency, and 0.34 times native glucagon potency

This needle-free option uses advanced absorption technology to deliver results comparable to injectable treatments, making it an ideal choice for patients who prefer to avoid shots or need a more travel-friendly routine

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) Diabet Med

Primary Phase 2 Obesity Trial: Jastreboff AM, Aronne LJ, Ahmad NN, et al